Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor?
暂无分享,去创建一个
M. Østergaard | J. Pødenphant | U. Tarp | M. Hetland | A. Hansen | H. Lindegaard | E. Peen | A. Rødgaard | L. Andersen | V. Ringsdal | J. Unkerskov | J. Bing | E. Hjardem | J. Skøt | H. H. Mogensen | Janne Unkerskov